论文部分内容阅读
目的:观察重组人血管内皮抑素(YH-16)联合长春瑞滨和顺铂(NP)治疗Ⅲb-Ⅳ期非小细胞肺癌(non-small cell carcinoma,NSCLC)的近期临床疗效及安全性。评价治疗前、后外周血癌胚抗原(carcino-embryonic antigen,CEA)在NSCLC治疗中的价值。方法:应用YH-16联合NP方案治疗晚期NSCLC共34例,统计临床有效率、临床收益率、生存质量并比较治疗前后外周血CEA水平。结果:34例患者临床有效率为14.71%(5/34),临床收益率为70.59%(24/34),治疗后生存质量明显提高且差异具有统计学意义(P<0.05)。34例患者血清CEA水平从治疗前(57.30±4.93)ng/ml下降到第2周期治疗后(15.64±7.50)ng/ml,两组CEA水平相比差异有统计学意义(P<0.05)。结论:YH-16联合NP方案治疗晚期NSCLC是合理、安全、有效的。CEA可能是一个预测YH-16联合NP方案治疗NSCLC疗效的标志物。
Objective: To observe the recent clinical efficacy and safety of recombinant human endostatin (YH-16) combined with vinorelbine and cisplatin (NP) in the treatment of stage Ⅲb-Ⅳ non-small cell carcinoma (NSCLC). To evaluate the value of carcinoembryonic antigen (CEA) in the treatment of NSCLC before and after treatment. Methods: A total of 34 cases of advanced non-small cell lung cancer (NSCLC) treated with YH-16 combined with NP regimen were enrolled in this study. Clinical efficiency, clinical benefit and quality of life were compared. CEA levels in peripheral blood before and after treatment were compared. Results: The clinical effective rate was 14.71% (5/34) in 34 patients, and the clinical rate of return was 70.59% (24/34). After treatment, the quality of life was significantly improved and the difference was statistically significant (P <0.05). Serum CEA levels in 34 patients decreased from 57.30 ± 4.93 ng / ml before treatment to 15.64 ± 7.50 ng / ml after 2 cycles. There was significant difference in CEA levels between the two groups (P <0.05). Conclusion: YH-16 combined with NP regimen in the treatment of advanced NSCLC is reasonable, safe and effective. CEA may be a prediction of the efficacy of YH-16 combined with NP regimen in the treatment of NSCLC.